What REACT Neuro does

REACT Neuro is a digital health company that has built a multimodal neurocognitive assessment platform for evaluating brain health. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company serves two primary customer segments: healthcare providers and brain health organizations that need non-invasive, remote-capable cognitive assessment (including early detection of Alzheimer's disease and neurodegeneration), and sports organizations and athletic programs that require objective concussion evaluation and ongoing brain-health monitoring for athletes. The founding team is drawn from Harvard Medical School and Massachusetts General Hospital, and the company positions itself around home-based deployment rather than clinic-only assessment.

The company's core offering is the REACT Neuro Platform, which combines virtual reality-based cognitive tasks with machine learning and a proprietary eye-tracking measurement layer called RETINA. RETINA is a granted/registered patented technology, with Mark Ettenhofer as lead inventor, that unobtrusively captures eye movements, pupil responses, and body movements during cognitively challenging VR scenarios to produce brain-health and mental-performance assessments; the Robot Challenge Screen is one assessment module within the platform. Research and clinical collaborations with Massachusetts General Hospital, Harvard Medical School, the UC Davis MIND Institute, and the Defense Health Agency Traumatic Brain Injury Center of Excellence (TBICoE) provide scientific credibility and a pipeline into military and clinical TBI work.

REACT Neuro is a privately held company with 11–50 employees, and pricing is not publicly disclosed. The company has limited disclosed funding activity, with one recorded accelerator participation (PharmStars, July 2022). Capital and commercial relationships are oriented through DRADS Capital (a fund co-founded by CEO Shaun Patel), BOLD Capital Partners (via advisor Felicia Hsu and Peter Diamandis), and senior digital health executives from Humana and Becton Dickinson, suggesting a go-to-market strategy that spans healthcare systems, payers, sports organizations, and federal health programs rather than a single-channel sales motion.

Name

REACT Neuro

Legal name

REACT Neuro Inc.

Website

https://reactneuro.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

REACT Neuro is a digital health company combining virtual reality, machine learning, and its patented RETINA eye-tracking technology to assess brain health. Founded by Harvard and Massachusetts General Hospital neuroscientists, it serves healthcare providers, sports organizations, and research institutions.

Ownership category

akta.pro rank

Product category

Digital Neurocognitive Assessment Software

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK), Dementia Companion & Engagement Care (HSABAEAA)

Keywords

• Digital brain health
• Neurocognitive assessment
• Concussion management
• Virtual reality therapy
• Brain health platform

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels4 records

Core offering

REACT Neuro provides a digital neurocognitive brain assessment platform that combines virtual reality cognitive tasks with its patented RETINA technology, which unobtrusively measures eye movements, pupil responses, and body movements to produce quick, quantitative assessments of brain health and mental performance. The platform is intended to be used from home or in clinical/sports settings to evaluate concussion, cognitive decline, Alzheimer's risk, and overall brain function for healthcare providers and sports organizations.

Product overview

REACT Neuro is a digital health company offering a unified platform that combines virtual reality and machine learning to assess and treat brain health. The core platform integrates the patented RETINA technology, which measures eye movements, pupil responses, and body movements during VR-based cognitive challenges. The Robot Challenge Screen is one assessment component within this platform.

Differentiator

Problem solved

Functional benefit

Products and services

• REACT Neuro Platform A digital health platform leveraging virtual reality and machine learning to assess and treat brain health from home. It uses VR-based cognitive assessments combined with eye tracking and physiological measurements to evaluate brain health for healthcare providers, brain health organizations, and sports programs.
• RETINA Technology A patented technology that unobtrusively measures eye movements, pupil responses, and body movements during cognitively challenging VR tasks to provide quick and accurate assessments of brain health and mental performance.
• Robot Challenge Screen A VR-based cognitive assessment screen within the REACT Neuro platform used for brain health evaluation, engaging the user in a cognitive challenge while RETINA technology captures eye, pupil, and body movement data.

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Eight partnerships are on record, tiered minor and core.

• HumanaminorOthersDave Icke, REACT Neuro advisor, currently leads Digital Health Product for Humana, a leading health plan and care delivery company for seniors.
• Becton Dickinson (BD)minorOthersDave Icke, REACT Neuro advisor, previously led the Digital Health Business Unit at BD, focusing on consumer-centric digital solutions outside the hospital.
• CogniviveminorStrategic or Co-development PartnerUC Davis-backed neurotherapeutics company founded by Tony Simon (REACT Neuro Chief Science Translation Officer) developing personalized, self-adapting prescription digital therapeutics delivered as VR games for neurocognitive improvement.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerMultiple REACT Neuro co-founders and advisors (Shaun Patel, Rudy Tanzi, Brian Nahed) hold positions at MGH and Harvard Medical School. Core research and clinical expertise originates from this institution.
• Harvard Medical SchoolcoreStrategic or Co-development PartnerCore team members (Shaun Patel former faculty, Rudy Tanzi as Professor, Brian Nahed as Associate Professor) are affiliated with Harvard Medical School, providing research and clinical credibility.
• UC Davis MIND InstituteminorStrategic or Co-development PartnerTony Simon (REACT Neuro Chief Science Translation Officer) served as Associate Director of the UC Davis MIND Institute and founded Cognivive through this academic affiliation.
• Defense Health Agency Traumatic Brain Injury Center of Excellence (TBICoE)minorStrategic or Co-development PartnerDr. Mark Ettenhofer serves as Senior Research Neuropsychologist at Naval Medical Center San Diego's TBICoE, collaborating on brain health research.
• XPRIZE FoundationminorOthersPeter Diamandis, REACT Neuro advisor, is founder and executive chairman of XPRIZE Foundation, a leading organization in incentive competitions for transformative technologies.

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cumulus Neuroscience: Multimodal digital biomarker platform for CNS clinical trials combining cognitive testing, EEG, and voice/behavioral measures. Closely comparable technology category (multimodal digital biomarkers for brain health) with a primary focus on pharma-sponsored CNS clinical trials, which aligns with REACT Neuro's pharma-services optionality.
• Linus Health: Digital brain health platform combining tablet-based cognitive testing with speech and voice biomarkers for early detection of Alzheimer's and other dementias. Directly comparable in target use case (Alzheimer's/cognitive decline detection) and customer base (healthcare providers, payors), with a similar multi-modal biomarker strategy.
• SyncThink: VR-based objective eye-tracking concussion assessment platform with FDA clearance and established sports/clinical deployments. Directly comparable technology stack (VR + eye tracking for brain assessment) and overlapping customer segments in sports and clinical concussion management — represents a more mature, FDA-cleared competitor.
• Cambridge Cognition: Publicly listed (AIM) digital cognitive testing company serving pharmaceutical clinical trials and healthcare providers. Closely comparable product category (digital cognitive assessment) with established clinical-trial-services revenue and FDA-cleared components — represents a more advanced, scaled version of REACT Neuro's clinical-research ambitions.
• HeadCheck Health: Digital concussion management platform used by sports organizations for sideline assessment and recovery tracking. Comparable in the sports concussion use case that REACT Neuro targets, with a mobile-first delivery model and established deployment across professional and amateur sports.
• Cognivue: FDA-cleared computerized cognitive assessment device used in primary care and specialty clinics for early detection of cognitive impairment. Directly comparable in healthcare-provider use case and dementia screening positioning, with the regulatory clearance REACT Neuro currently lacks.
• ImPACT Applications: Market-leading computerized concussion assessment tool used across professional sports (including the NFL), collegiate athletics, and K–12. Directly comparable in the sports concussion use case that REACT Neuro targets via Brian Nahed's NFL affiliation, and represents the entrenched competitor in this vertical.
• BrainCheck: Digital cognitive assessment platform used by healthcare systems and clinicians to screen for cognitive impairment and concussion. Directly comparable in use case (cognitive/neurocognitive assessment) and customer base (healthcare providers), with a more mature commercialization footprint and tablet-based delivery.

Broad incumbents

• Akili Interactive: Publicly listed (formerly Nasdaq) digital therapeutics company with FDA-cleared, prescription cognitive treatment products (e.g., EndeavorRx for ADHD). Comparable as a digital brain-health platform with regulatory clearance and commercial-scale deployment, representing a broader digital-therapeutic incumbent rather than a direct assessment competitor.

Emerging players

• Altoida: Digital biomarker company using augmented reality on smartphones/iPads to predict conversion from mild cognitive impairment to Alzheimer's. Comparable use case (Alzheimer's early detection) and customer base (pharma and clinical), but with a different delivery modality (AR vs. VR) and emerging-stage regulatory positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Instagraminstagram.com/reactneuro
• Facebookfacebook.com/REACTNeuro

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REACT Neuro